Search Results

Text Size:A- A+ Thank you dear subscribers, we are overwhelmed with your response.

Amidst a global push for mass vaccination as the battle against COVID-19 rages on many people are still afraid to be vaccinated. People remain concerned about the perceived experimental nature of vaccines, whether they should be worried about short term risks such as blood clotting and myocarditis; and long term risks including side effects relating to DNA changes, fertility and reproduction, and other unknown long term chronic illnesses and side effects further down the track.

You're about to hear advice from the last people you'd ever want to meet.

Mary Newman, former SVP of Regulatory Affairs at Astellas Gene Therapies, joins Taysha with over 30 years of experience in regulatory affairs and research and development in the biotech industry Extensive experience deeply rooted in gene therapy at Astellas Gene Therapies, Audentes Therapeutics and BioMarin DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the most recent addition to its leadership team with the appointment of industry veteran Mary Newman as Chief Development Officer. Ms.

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the publication of new preclinical data for TSHA-102 in Rett syndrome. The data were published online and will be included in the May edition of Brain, a highly esteemed neurological science peer-reviewed journal

CLEVELAND When 61-year-old Ken Anderson was diagnosed with Multiple Myeloma 3 years ago, he didnt know what to expect. It kind of hits you. It hits you hard, he said.

TEHRAN For the first time, MAHAK Charity Foundation has started using the Total Body Irradiation (TBI) cancer treatment method for children in the country.

TEL AVIV While the SARS-CoV-2 coronavirus grabbed center stage over this past year, biotech startup eggXYt turned its attention to avian influenza the deadly bird flu thats led to the slaughter of millions of infected poultry and also threatens human health. A new licensing agreement will enable eggXYt to develop genetic resistance in chickens against avian influenza virus using a technology known as gene editing induced gene silencing from U.K.-based Tropic Biosciences.

Jan. 26, 2021 12:00 UTC Timothy J. Douros, J.D., former General Counsel at Bluebird Bio, joins as Chief Legal Officer and Corporate Secretary, brings over 25 years of legal experience in the biotech industry Tracy M

Introduction Chronic myeloid leukemia (CML) is a hematological malignancy that develops when the 9;22 translocation in a single hematopoietic stem cell (HSC) results in the expression of BCR-ABL1 tyrosine kinase fusion protein. If left untreated, CML progresses over approximately 5 years, from relatively benign chronic phase to accelerated phase, and then to fatal blast crisis. The introduction of tyrosine kinase inhibitors (TKIs) specifically targeting the BCR-ABL1 fusion protein was a breakthrough in the management of CML, leading to a significant reduction in mortality and improved 5-year survival rates

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that it has received both rare pediatric disease and orphan drug designations from the U.S.

SAN FRANCISCO--(BUSINESS WIRE)--AllStripes (formerly RDMD), a healthcare technology company dedicated to accelerating research for patients with rare diseases, today announced a multiyear collaboration with Taysha Gene Therapies, Inc.

TSHA-101 will be the first bicistronic vector to enter a first-in-human clinical study, which is a significant milestone for Taysha and for the field of gene therapy, said Suyash Prasad, MBBS, M.SC., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha. GM2 is a devastating lysosomal storage disease with no approved treatments and todays CTA approval marks a formative moment for children suffering from this rapidly progressive and fatal disease.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--HighPassBio, an ElevateBio portfolio company dedicated to advancing novel targeted T cell immunotherapies, today discussed the ongoing Phase 1 trial of the companys lead product candidate, an engineered T cell receptor (TCR) T cell therapy targeting HA-1 expressing cancer cells in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting.

Nov. 24, 2020 12:00 UTC Appoints former Chief Medical Officer of Spark Therapeutics, Kathy Reape, M.D., and Chief Scientific Officer of Intellia Therapeutics, Laura Sepp-Lorenzino, Ph.D., to board of directors Directors bring significant gene therapy translational and development expertise ahead of GM2 gangliosidosis clinical trial initiation in 2020 and submission of four INDs by the end of 2021 DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc

Among the imminent miseries worldwide, the mortalities and morbidities caused by the combination of covid-19 and Diabetes Mellitus are considered to be the most tragic.

Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 About Regenerative Medicine Advanced Therapy (RMAT) DesignationEstablished under the 21st Century Cures Act, the RMAT designation was established to facilitate development and expedite review of cell therapies and regenerative medicines intended to treat serious or life-threatening diseases or conditions. Advantages include the benefits of the FDA's Fast Track and Breakthrough Therapy Designation programs, such as early interactions with the FDA to discuss potential surrogate or intermediate endpoints to support accelerated approval. About HDT-AHCT High-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT) is considered a standard-of-care therapy for patients with aggressive systemic Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).Although efficacious and considered a potential cure, HDT-AHCT is associated with severe regimen-related toxicities (SRRT) that increase patient morbidity and risk for mortality, especially in the aging population

As my colleagues and I first described in 2014, we can use CRISPR genome editing to duplicate the most powerful form of gene drive, a ubiquitous natural phenomenon that happens when a genetic change is inherited more frequently than usual.

by Manasi Vaidya in New York. Fate TherapeuticsandCelyadsnatural killer (NK) cell biology-focused cell therapies could overcome cell persistence challenges and consequent efficacy concerns with redosing strategies, experts said

Oct. 14, 2020 11:00 UTC DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies Inc

Are you stressed, anxious, or depressed? Do you have trouble sleeping? Do you have skin and hair problems

publication date: Oct. 9, 2020 In a new clinical trial, City of Hope is investigating a treatment for cancer patients with COVID-19 by repurposing leflunomide, an anti-inflammatory drug for rheumatoid arthritis, which is inexpensive and has few serious side effects. Patients treated for cancer in the past two years may also be eligible.

Find out what the pros had to say. You never forget your first. Grey hair, that is

Detect Lysosomal Storage Diseases program reduces barriers to genetic diagnosis through sponsored testing for lysosomal storage disorders, including GM2 gangliosidosis Behind the Seizure program can help accelerate genetic epilepsy diagnosis in children experiencing unprovoked seizures Taysha Gene Therapies Inc.

We're so close to eradicating polio.